Payment overview · 2025
General Payments
$286.52
10 reported records · 6 companies
Healthcare provider profile · identity verified
Jaime Esquivel, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SAN ANTONIO, TX · NPI 1457516460
Verified facts
What the public records show
CMS Open Payments records show Jaime Esquivel, M.D. received $286.52 in general payments during 2025 across 10 reported records.
Lilly USA, LLC accounted for 50.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trulicity by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $143.81 | 50.2% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $77.41 | 27.0% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.42 | 6.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.45 | 5.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.84 | 5.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.59 | 5.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $286.52 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $143.81 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $77.41 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.42 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
69 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 568 | 258 |
| Levothyroxine Sodium | Levothyroxine Sodium | 435 | 189 |
| Lisinopril | Lisinopril | 371 | 151 |
| Amlodipine Besylate | Amlodipine Besylate | 352 | 156 |
| Losartan Potassium | Losartan Potassium | 348 | 153 |
| Gabapentin | Gabapentin | 339 | 138 |
| Metformin Hcl | Metformin Hcl | 324 | 133 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 257 | 118 |
| Simvastatin | Simvastatin | 257 | 104 |
| Montelukast Sodium | Montelukast Sodium | 228 | 102 |
| Omeprazole | Omeprazole | 220 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 213 | 95 |
| Hydrochlorothiazide | Hydrochlorothiazide | 211 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 176 | 72 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 171 | 68 |
| Furosemide | Furosemide | 160 | 76 |
| Metoprolol Tartrate | Metoprolol Tartrate | 159 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 150 | 64 |
| Trazodone Hcl | Trazodone Hcl | 136 | 54 |
| Glipizide | Glipizide | 132 | 61 |
| Tramadol Hcl | Tramadol Hcl | 132 | 56 |
| Sertraline Hcl | Sertraline Hcl | 130 | 52 |
| Carvedilol | Carvedilol | 123 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 118 | 64 |
| Clopidogrel | Clopidogrel Bisulfate | 116 | 44 |
| Famotidine | Famotidine | 115 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 110 | 50 |
| Tizanidine Hcl | Tizanidine Hcl | 105 | 34 |
| Ibuprofen | Ibuprofen | 102 | 51 |
| Metformin Hcl Er | Metformin Hcl | 96 | 41 |
| Meloxicam | Meloxicam | 91 | 44 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 89 | 54 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 87 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 35 |
| Alendronate Sodium | Alendronate Sodium | 81 | 35 |
| Myrbetriq | Mirabegron | 80 | 20 |
| Prednisone | Prednisone | 76 | 45 |
| Clonazepam | Clonazepam | 74 | 24 |
| Jardiance | Empagliflozin | 69 | 25 |
| Eliquis | Apixaban | 68 | 37 |
| Allopurinol | Allopurinol | 67 | 32 |
| Pioglitazone Hcl | Pioglitazone Hcl | 67 | 34 |
| Glimepiride | Glimepiride | 64 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 28 |
| Ozempic | Semaglutide | 60 | 17 |
| Enalapril Maleate | Enalapril Maleate | 59 | 27 |
| Potassium Chloride | Potassium Chloride | 59 | 28 |
| Mirtazapine | Mirtazapine | 56 | 28 |
| Alprazolam | Alprazolam | 54 | 19 |
| Azithromycin | Azithromycin | 53 | 49 |
| Oxybutynin Chloride | Oxybutynin Chloride | 53 | 25 |
| Celecoxib | Celecoxib | 52 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 46 |
| Nifedipine Er | Nifedipine | 51 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 49 | 44 |
| Januvia | Sitagliptin Phosphate | 49 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 21 |
| Trulicity | Dulaglutide | 48 | 14 |
| Pregabalin | Pregabalin | 47 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 20 |
| Glipizide Er | Glipizide | 45 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 45 | 19 |
| Finasteride | Finasteride | 43 | 17 |
| Baclofen | Baclofen | 41 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 21 |
| Spironolactone | Spironolactone | 41 | 19 |
| Telmisartan | Telmisartan | 41 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 40 | 19 |
| Warfarin Sodium | Warfarin Sodium | 40 | 14 |
| Buspirone Hcl | Buspirone Hcl | 38 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 37 | 11 |
| Lubiprostone | Lubiprostone | 37 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 27 |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | 15 |
| Lovastatin | Lovastatin | 34 | 15 |
| Bydureon Bcise | Exenatide Microspheres | 33 | suppressed |
| Fluconazole | Fluconazole | 33 | 23 |
| Naproxen | Naproxen | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 18 |
| Temazepam | Temazepam | 29 | suppressed |
| Atenolol | Atenolol | 28 | 13 |
| Chlorthalidone | Chlorthalidone | 28 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | 14 |
| Donepezil Hcl | Donepezil Hcl | 27 | 12 |
| Memantine Hcl | Memantine Hcl | 27 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 26 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | 12 |
| Lorazepam | Lorazepam | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 21 |
| Benazepril Hcl | Benazepril Hcl | 23 | 11 |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Folic Acid | Folic Acid | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | 12 |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | 12 |
| Linzess | Linaclotide | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | 12 |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | 11 |
| Methocarbamol | Methocarbamol | 19 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Incontrol Pen Needle | Pen Needle, Diabetic | 16 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Leflunomide | Leflunomide | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $286.52 · 10 records | Lilly USA, LLC | AREXVY, CAPVAXIVE, GEMTESA, KISUNLA, Kerendia, OTEZLA, REPATHA, SHINGRIX | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error